Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children

Antivir Ther. 2004 Apr;9(2):297-9.

Abstract

We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Alkynes
  • Antiretroviral Therapy, Highly Active*
  • Benzoxazines
  • Child
  • Child, Preschool
  • Cyclopropanes
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects
  • Humans
  • Lopinavir
  • Oxazines / adverse effects
  • Oxazines / therapeutic use*
  • Pyrimidinones / adverse effects
  • Pyrimidinones / therapeutic use*
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use*
  • Treatment Outcome

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Oxazines
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • efavirenz
  • Ritonavir